Achieving optimum lipid-lowering goals in patients with vascular disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Individuals with established cardiovascular disease are at high risk for serious adverse ischemic events. Fortunately, effective control of serum cholesterol levels, especially low-density lipoprotein (LDL), can significantly reduce cardiovascular morbidity and mortality. To achieve these benefits, the evidence-based National Cholesterol Education Program-Adult Treatment Panel III Guidelines recommend an LDL goal of less than 100 mg/dL with a secondary non-high-density lipoprotein (HDL) goal of less than 130 mg/dL. The more aggressive optional goals are an LDL less than 70 mg/dL and a non-HDL of less than 100 mg/dL. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) exert potent LDL-lowering as well as pleiotropic effects, and these agents have consistently reduced cardiac mortality and myocardial infarction in trials of secondary prevention. Should a statin drug alone fail to achieve the goal due to resistance or patient intolerance, combination drug therapy can be used. Combination therapy may also help achieve secondary goals for the reduction of non-HDL cholesterol levels.
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–421.
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7–22.
- Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504. CrossRef
- Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239. CrossRef
- Langsted A, Freiberg JJ, Nordestgaard BG: Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008, 118:2047–2056. CrossRef
- Bansal S, Buring JE, Rifai N, et al.: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309–316. CrossRef
- Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299–308. CrossRef
- Krauss RM, Eckel RH, Howard B, et al.: AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000, 102:2284–2299.
- Jenkins DJ, Kendall CW, Marchie A, et al.: Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003, 290:502–510. CrossRef
- Poobalan A, Aucott L, Smith WC, et al.: Effects of weight loss in overweight/obese individuals and long-term lipid outcomes-a systematic review. Obes Rev 2004, 5:43–50. CrossRef
- Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278. CrossRef
- Brilakis ES, de Lemos JA, Cannon CP, et al.: Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). Am J Cardiol 2008, 102:552–558. CrossRef
- Kulik A, Brookhart MA, Levin R, et al.: Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 2008, 118:1785–1792. CrossRef
- Shah SJ, Waters DD, Barter P, et al.: Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol 2008, 51:1938–1943. CrossRef
- Johnson C, Waters DD, DeMicco DA, et al.: Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study). Am J Cardiol 2008, 102:1312–1317. CrossRef
- Ridker PM, Danielson E, Fonseca FA, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207. CrossRef
- Ballantyne CM, Raichlen JS, Nicholls SJ, et al.: Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation 2008, 117:2458–466. CrossRef
- Fellstrom BC, Jardine AG, Schmieder RE, et al.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395–1407. CrossRef
- Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238–248. CrossRef
- Jones P, Kafonek S, Laurora I, Hunninghake D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998, 81:582–587. CrossRef
- Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97:52C–60C. CrossRef
- Kashani A, Phillips CO, Foody JM, et al.: Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006, 114:2788–2797. CrossRef
- Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403–414. CrossRef
- Venero CV, Thompson PD:Managing statin myopathy. Endocrinol Metab Clin North Am 2009, 38:121–136. CrossRef
- Schaars CF, Stalenhoef AF: Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008, 19:553–557. CrossRef
- Gadarla M, Kearns AK, Thompson PD: Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008, 101:1747–1748. CrossRef
- Backes JM, Venero CV, Gibson CA, et al.: Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008, 42:341–346. CrossRef
- Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109:III50–57. CrossRef
- Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245–1255. CrossRef
- Brown BG, Zhao XQ: Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008, 101:58B–62B. CrossRef
- Davidson MH: Niacin use and cutaneous flushing: mechanisms and strategies for prevention. Am J Cardiol 2008, 101:14B–19B. CrossRef
- Bays H: Safety of niacin and simvastatin combination therapy. Am J Cardiol 2008, 101:3B–8B. CrossRef
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351–364.
- The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984, 251:365–374.
- Donovan JM, Stypinski D, Stiles MR, et al.: Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000, 14:681–690. CrossRef
- Dujovne CA, Ettinger MP, McNeer JF, et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1092–1097. CrossRef
- Kashani A, Sallam T, Bheemreddy S, et al.: Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol 2008, 101:1606–1613. CrossRef
- Jackevicius CA, Tu JV, Ross JS, et al.: Use of ezetimibe in the United States and Canada. N Engl J Med 2008, 358:1819–1828. CrossRef
- Kastelein JJ, Akdim F, Stroes ES, et al.: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431–1443. CrossRef
- Cannon CP, Giugliano RP, Blazing MA, et al.: Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156:826–832. CrossRef
- Fletcher B, Berra K, Ades P, et al.: Managing abnormal blood lipids: a collaborative approach. Circulation 2005, 112:3184–3209. CrossRef
- Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585–1591. CrossRef
- Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905–910.
- Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747–2757. CrossRef
- Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 1999, 354:447–455.
- Macchia A, Levantesi G, Franzosi MG, et al.: Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail 2005, 7:904–909. CrossRef
- Eritsland J, Arnesen H, Seljeflot I, Kierulf P: Long-term effects of n-3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagul Fibrinolysis 1995, 6:17–22. CrossRef
- Achieving optimum lipid-lowering goals in patients with vascular disease
Current Cardiovascular Risk Reports
Volume 3, Issue 5 , pp 323-330
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links